Pneumococcal Polysaccharide Vaccine
Authors: Y Van Laethem
Journal: Annals of Internal Medicine (1982)

Diagnosis and Treatment1 February 1982Pneumococcal Polysaccharide VaccineRecommendation of the Immunization Practices Advisory CommitteeAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-2-203 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractAbstractThe risk of pneumococcal infection differs in different age ranges; the risk and the severity of the infection increases in persons with certain chronic diseases. Penicillin remains the best antimicrobial agent for treatment. The recently developed pneumococcal polysaccharide vaccine represents 14 serotypes responsible for a large majority of pneumococcal infections in the United States. The efficacy of the vaccine has been demonstrated in a number of trials. This vaccine recommendation statement indicates the persons most likely to benefit from vaccination and reviews the adverse effects likely to occur and the precautions to be taken in administering the vaccine.References1. FRASERDARBYKOEHLERJACOBSFELDMAN DCRCR. Risk factors in bacterial meningitis: Charleston County, South Carolina. J Infect Dis. 1973;127:271-7. CrossrefMedlineGoogle Scholar2. FILICEDARBYFRASER GCD. Pneumococcal bacteremia in Charleston County, South Carolina. Am J Epidemiol. 1980;112:828-35. CrossrefMedlineGoogle Scholar3. BROOMEFACKLAM CR. Epidemiology of clinically significant isolates of Streptococcus pneumoniae in the United States. Rev Infect Dis. 1981;3:277-80. CrossrefMedlineGoogle Scholar4. ROBBINSLEERASTOGISCHIFFMANHENRICHSEN JCSGJ. Comparative immunogenicity of group 6 pneumococcal type 6A (6) and type 6B (26) capsular polysaccharides. Infect Immun. 1979;26:1116-22. CrossrefMedlineGoogle Scholar5. KAUFMAN P. Pneumonia in old age. Active immunization against pneumonia with pneumococcus polysaccharide; results of 6-year study. Arch Intern Med. 1947;79:518-31. CrossrefGoogle Scholar6. MACLEODHODGESHEIDELBERGERBERNHARD CRMW. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med. 1945;82:445-65. CrossrefGoogle Scholar7. AUSTRIANDOUGLASSCHIFFMAN RRG. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Phys. 1976;89:184-94. MedlineGoogle Scholar8. RILEYANDREWSHOWARD IMR. Immunization with a polyvalent pneumococcal vaccine: reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet. 1977;1:1338-41. CrossrefMedlineGoogle Scholar9. AUSTRIAN R. Surveillance of Pneumococcal Infection for Field Tests of Polyvalent Pneumococcal Vaccines. Washington, D.C.: National Institutes of Health; 1980. Google Scholar10. AMMANNADDIEGOWARALUBINSMITHMENTZER AJDBWW. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med. 1977;297:897-900. CrossrefMedlineGoogle Scholar11. BROOMEFACKLAMFRASER CRD. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med. 1980;303:549-52. CrossrefMedlineGoogle Scholar12. BORGONOMCLEANVELLA JAP. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants (40010). Proc Soc Exp Bio Med. 1978;157:148-54. CrossrefMedlineGoogle Scholar13. MUFSONKRAUSETARRANTSCHIFFMANCANO MHCGF, Polyvalent pneumococcal vaccine given alone in combination with bivalent influenza virus vaccine (40804). Proc Soc Exp Biol Med. 1980;163:498-503. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: ▸From the Immunization Practices Advisory Committee, Centers for Disease Control: Atlanta, Georgia PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byVaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccineChronic Obstructive Airways DiseaseAntibody response to pneumococcal polysaccharide vaccine in Myasthenia gravis: Effect of therapeutic plasmapheresisImmunization, Immunoprophylaxis, and Chemoprophylaxis to Prevent Selected InfectionsDisease Prevention and Health MaintenanceInefficacy of pneumococcal vaccine in a high-risk populationPneumococcal serotypes in sputum isolates during acute respiratory illness in Edinburgh.Immunizing the adultPneumococcal Vaccine Efficacy in Selected Populations in the United StatesGAIL BOLAN, M. D., CLAIRE V. BROOME, M.D., RICHARD R. FACKLAM, Ph.D, BRIAN D. PLIKAYTIS, M.S., DAVID W. FRASER, M.D., WALTER F. SCHLECH III, M.D.Surgical Diseases of the SpleenPneumococcal Pneumonia and Septicemia Resulting from a Nontypable Strain of PneumococcusA Controlled Evaluation of the Protective Efficacy of Pneumococcal Vaccine for Patients at High Risk of Serious Pneumococcal InfectionsEUGENE D. SHAPIRO, M.D., JOHN D. CLEMENS, M.D.Pneumococcal Vaccination: The Response of Patients with Alcoholic Liver CirrhosisPulmonary disease in polymyositis/dermatomyositisManagement of the Immunocompromised HostCommunity-Acquired Bacterial Pneumonia in the ElderlyHodgkin’s DiseaseAntibody responses to meningococcal polysaccharide vaccine in adults without a spleenGeriatric Infectious DiseasesRecent advances in respiratory medicine.Pneumococcal Vaccine: Clinical Efficacy and EffectivenessJ. SANFORD SCHWARTZ, M.D. 1 February 1982Volume 96, Issue 2Page: 203-205KeywordsAntimicrobialsInfectious disease controlPenicillinPolysaccharidesVaccines ePublished: 1 December 2008 Issue Published: 1 February 1982 PDF downloadLoading ...